Fate Therapeutics
FATE
167 hedge funds and large institutions have $904M invested in Fate Therapeutics in 2024 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 48 increasing their positions, 52 reducing their positions, and 31 closing their positions.
324% more call options, than puts
Call options by funds: $1.69M | Put options by funds: $399K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
150% more capital invested
Capital invested by funds: $362M → $904M (+$542M)
32% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 31
25.92% more ownership
Funds ownership: 98.19% → 124.12% (+26%)
5% more funds holding
Funds holding: 159 → 167 (+8)
8% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 52
Top Buyers
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$47.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$38.2M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$34.5M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$15.9M |
| 5 |
Holocene Advisors
New York
|
+$15.6M |
Top Sellers
| 1 |
BlackRock
New York
|
-$13.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.8M |
| 3 |
MAM
Monaco Asset Management
Monaco
|
-$11.6M |
| 4 |
Two Sigma Investments
New York
|
-$7.96M |
| 5 |
CC
Casdin Capital
New York
|
-$7.67M |
FATE Hedge Fund Activity: Q1 2024 in Review
167 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2024, worth a combined $904M — up 150% from $362M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new FATE positions and 31 closed out — a net gain of 10 holders — while 48 added to existing stakes and 52 trimmed.
The largest buyer was Boxer Capital, adding an estimated $47.8M. The largest seller was BlackRock, cutting an estimated $13.1M.
- 167 institutional investors held Fate Therapeutics (FATE) as of Q1 2024, up from 159 in Q4 2023.
- Funds reported $904M of Fate Therapeutics stock for Q1 2024, up 150% quarter-over-quarter.
- 41 funds opened new Fate Therapeutics positions in Q1 2024 and 31 closed out, a net change of +10 holders.
- The largest Fate Therapeutics buyer in Q1 2024 was Boxer Capital, an estimated $47.8M added.
- The largest Fate Therapeutics seller in Q1 2024 was BlackRock, an estimated $13.1M sold.
Based on aggregated 13F filings for Q1 2024.